Katherine Welles / Shutterstock.com
22 September 2020AmericasRory O'Neill
BMS and Dr Reddy’s settle Revlimid suit with generics licence
Bristol Myers Squibb (BMS) and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid (lenalidomide).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.
Americas
4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
9 May 2023 Decision addresses issue of plausibility in invalidation verdict |
Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
Editor's picks
Editor's picks
Americas
6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.
Americas
4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
9 May 2023 Decision addresses issue of plausibility in invalidation verdict |
Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
Americas
6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.
Americas
4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
9 May 2023 Decision addresses issue of plausibility in invalidation verdict |
Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.